4/A: Ionis Pharmaceuticals Executive Revises Stock Sale Details in Amended SEC Filing
SEC Filing
Onaiza Cadoret-Manier, EVP at Ionis Pharmaceuticals, amends a previous SEC filing to correct the number of shares sold and beneficially owned.
Summary
- Onaiza Cadoret-Manier, an Executive Vice President at Ionis Pharmaceuticals, filed an amendment to a Form 4 initially submitted on February 2, 2024.
- The amendment corrects the number of common stock shares sold on February 2, 2024, and the amount of securities beneficially owned following the transaction.
- The corrected filing indicates that 2,162 shares were sold at a weighted average price of $49.602.
- Following the reported transaction, Ms. Cadoret-Manier beneficially owns 35,788 shares of Ionis Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a previous error, and does not contain information that would significantly impact investor sentiment.
Industry Context
This filing is a routine disclosure related to insider trading activity and provides transparency to the market regarding the transactions of company executives.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date of original transaction and initial Form 4 filing. |
| 02/02/2024 | Date of amended transaction. |
| 09/04/2024 | Date of amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.